Rod-mediated Dark Adaptation as a Functional Biomarker for Early AMD

March 26

Tuesday, 12:30 pm

Billings Building—Rosedale Room

SPEAKER:

Cynthia Owsley Ph.D., MSPH

Nathan E. Miles Endowed Chair of Ophthalmology

Director, Clinical Research Unit/ Department of Ophthalmology and Visual Sciences

Callahan Eye Hospital & Clinics

Heersink School of Medicine

UAB | The University of Alabama at Birmingham

Host: Glen Prusky, Ph.D.

For more information contact
Darlene White
daw9085@med.cornell.edu

Abstract

Approved strategies for reducing the burden of age-related macular degeneration (AMD) focus on preventing or stabilizing neovascularization and slowing the progression of preexisting atrophy. Yet, the vast majority of people with AMD have earlier disease. I will describe my research over the past 20 years addressing a psychophysical test, rod-mediated dark adaptation, that is linked to early and intermediate AMD, which potentially could be used as a functional endpoint in trials focused on early disease. I will also describe how rod-mediated dark adaptation is linked to structural characteristics of AMD in its earlier phases.

Publications

1. Owsley C, Swain TA, Kar D, Curcio CA. *Rod mediated dark adaptation, a functional test for early and intermediate AMD outcomes.* Expert Review of Ophthalmology, 2024; 19(1): 1-5.

2. Owsley C, Swain TA, McGwin G Jr, Clark ME, Kar D, Crosson JN, Curcio CA. *How vision is impaired from aging to early and intermediate age-related macular degeneration: Insights from ALSTAR2 baseline.* Translational Vision and Technology 2022;11: 17.

3. Owsley C, Swain TA, McGwin G Jr, Clark ME, Kar D, Curcio CA. *Biologically guided optimization of test target location for rod-mediated dark adaptation in age-related macular degeneration: ALSTAR2.* Ophthalmology Science 2022; 3: 100274.

Burke Neurological Institute — The Science Hope Demands

Weill Cornell Medicine